Depression, TMS, Psychotherapy and Brain Function Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. This research study seeks depressed participants to test the effects of the combination of repetitive transcranial magnetic stimulation (TMS) and psychotherapy on brain function. This study is enrolling eligible adults … Continue reading Depression Research Opportunity
Depression Research Opportunity
Major Depression and AV101 Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 (an antagonist of the glycine receptor) versus placebo. The study aims to determine … Continue reading Depression Research Opportunity
Join NIMH Study on Major Depression
A Shorter—but Effective—Treatment for PTSD
A Shorter—but Effective—Treatment for PTSD Study finds written exposure therapy may be as effective as a lengthier first-line intervention Research supported by the National Institute of Mental Health has shown that a shorter therapy (written exposure therapy) may be just as effective as lengthier first-line treatments for PTSD. Learn more >>
Study Suggests Cannabis Compound Can Make Schizophrenia Medication Less Effective
Jonathon C. Arnold, Ph.D. University of Sydney, Australia 2009 Young Investigator Grant New research in mice reveals how THC, the main psychoactive compound in cannabis, can reduce the effectiveness of risperidone, an antipsychotic drug used widely to treat people with schizophrenia. Earlier studies have suggested that cannabis use can reduce the effectiveness of antipsychotic treatments and … Continue reading Study Suggests Cannabis Compound Can Make Schizophrenia Medication Less Effective
Depression Research Opportunity
Depression, Repeated Doses of Ketamine, and Neuroimaging Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. The purpose of this study is to evaluate the rapid and sustained antidepressant effects of repeat doses of ketamine in the brain. We want to learn how ketamine affects … Continue reading Depression Research Opportunity
Depression Research Opportunity
Join a Research Study: Enrolling nationally from around the country. The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 versus placebo. The study aims to determine if this experimental drug has antidepressant effects and fewer side effects than other novel treatments for depression. First steps to participate include calling NIMH, learning specifics about the study, asking about your eligibility, and consenting to participate.
Clinical Trial: Major Depression and AV101
The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 (an antagonist of the glycine receptor) versus placebo. The study aims to determine if this experimental drug has antidepressant effects and fewer side effects than other novel treatments for depression.
Depression Research Opportunity
The purpose of this study is to evaluate the rapid and sustained antidepressant effects of repeat doses of ketamine in the brain. We want to learn how ketamine affects areas of the brain important in regulating mood and if there are unique signatures that could help predict who may respond to the drug.
Circuitry for Fearful Feelings, Behavior Untangled in Anxiety Disorders
An “incorrect” assumption that fear and anxiety are mediated in the brain by a single “fear circuit” may have stalled progress in developing better treatments for anxiety disorders.
